HUTCHMED (HCM) Competitors

HUTCHMED (NASDAQ:HCM) and Viatris (NASDAQ:VTRS) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, community ranking, media sentiment, profitability, dividends, risk and institutional ownership.

Do analysts recommend HCM or VTRS?

HUTCHMED presently has a consensus target price of $19.00, suggesting a potential upside of 60.88%. Viatris has a consensus target price of $10.50, suggesting a potential upside of 42.66%. Given HUTCHMED's stronger consensus rating and higher possible upside, equities research analysts plainly believe HUTCHMED is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Viatris	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Which has more volatility & risk, HCM or VTRS?

HUTCHMED has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.

Is HCM or VTRS more profitable?

HUTCHMED has a net margin of 0.00% compared to Viatris' net margin of -5.87%. Viatris' return on equity of 16.46% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Viatris	-5.87%	16.46%	7.09%

Do institutionals and insiders hold more shares of HCM or VTRS?

8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 3.6% of HUTCHMED shares are held by company insiders. Comparatively, 0.1% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the MarketBeat Community believe in HCM or VTRS?

HUTCHMED received 293 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 66.39% of users gave HUTCHMED an outperform vote while only 34.85% of users gave Viatris an outperform vote.

Company	Underperform	Outperform
HUTCHMED	Outperform Votes 316 66.39%	Underperform Votes 160 33.61%
Viatris	Outperform Votes 23 34.85%	Underperform Votes 43 65.15%

Which has better valuation & earnings, HCM or VTRS?

HUTCHMED has higher earnings, but lower revenue than Viatris.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$630.20M	3.27	$100.78M	N/A	N/A
Viatris	$14.74B	0.60	$54.70M	-$0.53	-13.89

Does the media prefer HCM or VTRS?

In the previous week, Viatris had 24 more articles in the media than HUTCHMED. MarketBeat recorded 27 mentions for Viatris and 3 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.13 beat Viatris' score of 0.01 indicating that HUTCHMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	2 Very Positive mention(s)	2 Positive mention(s)	18 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

HUTCHMED beats Viatris on 9 of the 16 factors compared between the two stocks.